We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for inf... read more Featured Products: More products

Download Mobile App





Seegene Highlights High-Throughput, Single Tube 8-Plex RT-PCR Test for Flu A, Flu B, RSV and COVID-19 with Dual Internal Controls

By LabMedica International staff writers
Posted on 16 Dec 2020
Print article
Illustration
Illustration
Seegene, Inc. (Seoul, Korea) highlighted its new high-throughput 8-plex test for Flu A, Flu B, RSV and COVID-19 with dual internal controls at the all virtual 2020 AACC Annual Scientific Meeting held on December 13-17.

Attendees of the 2020 AACC Virtual Meeting Platform viewed Seegene’s Allplex SARS-CoV-2/FluA/FluB/RSV Assay, a single tube real-time RT-PCR assay that simultaneously detects and differentiates Flu A, Flu B, RSV A/B, and three different target genes of COVID-19 (S gene, RdRP gene and N gene).

Given the similarity in terms of symptoms between seasonal flu and SARS-CoV-2, multiplexing capability will be a critical consideration to accommodate high volume testing necessary for effective disease control in preparation for flu season during COVID-19 pandemic. Seegene's assay incorporates its proprietary high multiplex chemistry technologies, maximizing sensitivity and specificity during PCR amplification and detection of multiple targets. Combined with its unique task target automated system and interpretation software solution, the company offers unparalleled capacity at the most competitive pricing available on the market.

The assay also includes dual targets for internal control (exogenous and endogenous, respectively) run in the same reaction tube, which allow verification of the whole test process as well as proper sampling. The assay is currently validated with a wide range of extraction systems (Seegene STARlet, Seegene NIMBUS, Microlab STARlet IVD, Microlab NIMBUS, Seeprep32, KingFisher Flex, MagNA Pure 96, NucliSENS EasyMag, GeneAll Ribospin vRD Viral RNA/DNA Extraction Kit, QIAamp DSP Viral RNA Mini kit) and plans to expand further upon market demand. For PCR instruments, Bio-Rad CFX96 systems can be used.

Seegene also offered a glimpse of its comprehensive syndromic product portfolio on the same automated solution, including its well-established syndromic respiratory virus/bacteria panels which simultaneously detect 26 different targets.


New
Gold Supplier
Automated Chemiluminescent Analyzer
BIO-FLASH
New
Silver Supplier
Urea Breath Test
13C-Urea Breath Test
New
Silver Supplier
Hemoglobin Testing System
VARIANT II TURBO
New
Automated Nucleic Acid Extraction System
GenoXtract fleXT

Print article

Channels

Molecular Diagnostics

view channel
Image: A new blood test could noninvasively and inexpensively detect colorectal cancer (Photo courtesy of Pexels)

Novel Blood Test Could Detect Early-Onset Colorectal Cancer

Colorectal cancer is the fourth most common cancer, according to the U.S. Centers for Disease Control and Prevention. The rate of colon or rectal cancers in people younger than 50 years old has been on... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.